ElielBayeverMDMRCP

Pediatric Hematology & Oncology • Monmouth Junction, NJ

Pediatric Hematologic Oncology, Pediatric Solid Tumor Oncology

Chief Medical Officer, Elucida Oncology, Inc.

Join to view full profile

Dr. Bayever is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bayever's full profile

Already have an account?

Office
Elucida Oncology, Inc.
1 Deer Park Drive, Suite E
Monmouth Junction, NJ 08852

Education & Training

University of the WitwatersrandClass of 1973

Certifications & Licensure

CA State Medical License 1992 - 2019

Clinical Trials

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment Start of enrollment: 2012 Nov 01
Completed
Phase 1

Publications & Presentations

PubMed

729 citations
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, ...
Andrea Wang-Gillam, Chung-Pin Li, György Bodoky, Andrew Dean, Yan Shen Shan
Lancet. 2016-02-06
16 citations
Treatment of aplastic anemia: results with bone marrow transplantation, antithymocyte globulin, and a monoclonal anti-T cell antibody.
Richard E. Champlin, Won Jin Ho, Eliel Bayever, Drew J. Winston, Carl Lenarsky
Progress in Clinical and Biological Research. 1984-01-01
32 citations
Comparison between bone marrow transplantation and antithymocyte globulin in treatment of young patients with severe aplastic anemia
Eliel Bayever, Richard E. Champlin, Winston G. Ho, Carl Lenarsky, Susan Storch
The Journal of Pediatrics. 1984-12-01

Press Mentions

Quest Announces That OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company's Lead Investigational Drug, Oregovomab, in Frontline Ovarian Cancer and Appoints Dr. Sunil Gupta as Chief Medical OfficerNovember 9th, 2020
Elucida Oncology Appoints Dr. Eliel Bayever as Chief Medical OfficerOctober 1st, 2020
OncoQuest Lays the Groundwork for Commencement of Phase 3 Study in Frontline Ovarian CancerFebruary 15th, 2019
Join now to see all